Gene-Chemical Interaction Annotations Click to see Annotation Detail View
Term | Qualifier | Evidence | With | Reference | Notes | Source | Original Reference(s) | (1->4)-beta-D-glucan | multiple interactions | ISO | Parpbp (Mus musculus) | 6480464 | [perfluorooctane sulfonic acid co-treated with Cellulose] results in increased expression of PARPBP mRNA | CTD | PMID:36331819 | 17beta-estradiol | multiple interactions | EXP | | 6480464 | [estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of PARPBP mRNA | CTD | PMID:32741896 | 17beta-estradiol 3-benzoate | multiple interactions | EXP | | 6480464 | [estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of PARPBP mRNA | CTD | PMID:32741896 | 2,2',4,4',5,5'-hexachlorobiphenyl | multiple interactions | ISO | Parpbp (Mus musculus) | 6480464 | [2 more ... | CTD | PMID:25510870 | 2,2',5,5'-tetrachlorobiphenyl | multiple interactions | ISO | Parpbp (Mus musculus) | 6480464 | [2 more ... | CTD | PMID:25510870 | 2,3,7,8-tetrachlorodibenzodioxine | affects expression | ISO | Parpbp (Mus musculus) | 6480464 | Tetrachlorodibenzodioxin affects the expression of PARPBP mRNA | CTD | PMID:26377647 | 2,3,7,8-tetrachlorodibenzodioxine | decreases expression | EXP | | 6480464 | Tetrachlorodibenzodioxin results in decreased expression of PARPBP mRNA | CTD | PMID:32109520 and PMID:33387578 | 2-palmitoylglycerol | increases expression | ISO | PARPBP (Homo sapiens) | 6480464 | 2-palmitoylglycerol results in increased expression of PARPBP mRNA | CTD | PMID:37199045 | 3-isobutyl-1-methyl-7H-xanthine | multiple interactions | ISO | PARPBP (Homo sapiens) | 6480464 | [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol S] results in decreased expression of PARPBP mRNA | CTD | PMID:28628672 | 4,4'-sulfonyldiphenol | multiple interactions | ISO | PARPBP (Homo sapiens) | 6480464 | [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol S] results in decreased expression of PARPBP mRNA | CTD | PMID:28628672 | acetamide | increases expression | EXP | | 6480464 | acetamide results in increased expression of PARPBP mRNA | CTD | PMID:31881176 | acrylamide | increases expression | EXP | | 6480464 | Acrylamide results in increased expression of PARPBP mRNA | CTD | PMID:28959563 | aflatoxin B1 | affects expression | ISO | PARPBP (Homo sapiens) | 6480464 | Aflatoxin B1 affects the expression of PARPBP protein | CTD | PMID:20106945 | aflatoxin B1 | increases expression | EXP | | 6480464 | Aflatoxin B1 results in increased expression of PARPBP mRNA | CTD | PMID:25378103 | aflatoxin M1 | decreases expression | ISO | PARPBP (Homo sapiens) | 6480464 | Aflatoxin M1 results in decreased expression of PARPBP mRNA | CTD | PMID:30928695 | all-trans-retinoic acid | decreases expression | ISO | PARPBP (Homo sapiens) | 6480464 | Tretinoin results in decreased expression of PARPBP mRNA | CTD | PMID:33167477 | aristolochic acid A | decreases expression | ISO | PARPBP (Homo sapiens) | 6480464 | aristolochic acid I results in decreased expression of PARPBP mRNA | CTD | PMID:33212167 | arsenite(3-) | multiple interactions | ISO | PARPBP (Homo sapiens) | 6480464 | arsenite promotes the reaction [G3BP1 protein binds to PARPBP mRNA] | CTD | PMID:32406909 | azathioprine | decreases expression | ISO | PARPBP (Homo sapiens) | 6480464 | Azathioprine results in decreased expression of PARPBP mRNA | CTD | PMID:22623647 | azoxystrobin | multiple interactions | EXP | | 6480464 | [azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased methylation of PARPBP gene | CTD | PMID:33854195 | benzo[a]pyrene | decreases expression | ISO | PARPBP (Homo sapiens) | 6480464 | Benzo(a)pyrene results in decreased expression of PARPBP mRNA | CTD | PMID:20064835 | benzo[a]pyrene | increases expression | ISO | Parpbp (Mus musculus) | 6480464 | Benzo(a)pyrene results in increased expression of PARPBP mRNA | CTD | PMID:32417428 | benzo[a]pyrene diol epoxide I | decreases expression | ISO | PARPBP (Homo sapiens) | 6480464 | 7 more ... | CTD | PMID:20382639 | bis(2-chloroethyl) sulfide | decreases expression | ISO | PARPBP (Homo sapiens) | 6480464 | Mustard Gas results in decreased expression of PARPBP mRNA | CTD | PMID:25102026 | bisphenol A | decreases expression | ISO | PARPBP (Homo sapiens) | 6480464 | bisphenol A results in decreased expression of PARPBP mRNA | CTD | PMID:25047013 and PMID:29275510 | bisphenol A | increases expression | EXP | | 6480464 | bisphenol A results in increased expression of PARPBP mRNA | CTD | PMID:32145629 | bisphenol A | decreases expression | EXP | | 6480464 | bisphenol A results in decreased expression of PARPBP mRNA | CTD | PMID:25181051 | cadmium dichloride | decreases expression | EXP | | 6480464 | Cadmium Chloride results in decreased expression of PARPBP mRNA | CTD | PMID:25993096 and PMID:33453195 | calcitriol | decreases expression | ISO | PARPBP (Homo sapiens) | 6480464 | Calcitriol results in decreased expression of PARPBP mRNA | CTD | PMID:21592394 | calcitriol | multiple interactions | ISO | PARPBP (Homo sapiens) | 6480464 | [Testosterone co-treated with Calcitriol] results in decreased expression of PARPBP mRNA | CTD | PMID:21592394 | carbon nanotube | increases expression | ISO | Parpbp (Mus musculus) | 6480464 | Nanotubes more ... | CTD | PMID:25554681 | chlorpyrifos | multiple interactions | EXP | | 6480464 | [azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased methylation of PARPBP gene | CTD | PMID:33854195 | chlorpyrifos | decreases expression | ISO | Parpbp (Mus musculus) | 6480464 | Chlorpyrifos results in decreased expression of PARPBP mRNA | CTD | PMID:37019170 | cobalt dichloride | increases expression | ISO | PARPBP (Homo sapiens) | 6480464 | cobaltous chloride results in increased expression of PARPBP mRNA | CTD | PMID:22941251 | cobalt dichloride | decreases expression | EXP | | 6480464 | cobaltous chloride results in decreased expression of PARPBP mRNA | CTD | PMID:24386269 | copper(II) sulfate | decreases expression | ISO | PARPBP (Homo sapiens) | 6480464 | Copper Sulfate results in decreased expression of PARPBP mRNA | CTD | PMID:19549813 | coumestrol | increases expression | ISO | PARPBP (Homo sapiens) | 6480464 | Coumestrol results in increased expression of PARPBP mRNA | CTD | PMID:19167446 | coumestrol | multiple interactions | ISO | PARPBP (Homo sapiens) | 6480464 | [Coumestrol co-treated with 2 more ... | CTD | PMID:19167446 | cyclosporin A | decreases expression | ISO | PARPBP (Homo sapiens) | 6480464 | Cyclosporine results in decreased expression of PARPBP mRNA | CTD | PMID:20106945 more ... | dexamethasone | multiple interactions | ISO | PARPBP (Homo sapiens) | 6480464 | [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol S] results in decreased expression of PARPBP mRNA | CTD | PMID:28628672 | diallyl trisulfide | decreases expression | ISO | PARPBP (Homo sapiens) | 6480464 | diallyl trisulfide results in decreased expression of PARPBP mRNA | CTD | PMID:34995734 | dicrotophos | decreases expression | ISO | PARPBP (Homo sapiens) | 6480464 | dicrotophos results in decreased expression of PARPBP mRNA | CTD | PMID:28302478 | dioxygen | decreases expression | ISO | PARPBP (Homo sapiens) | 6480464 | Oxygen deficiency results in decreased expression of PARPBP mRNA | CTD | PMID:26516004 | dioxygen | multiple interactions | EXP | | 6480464 | [dan-shen root extract co-treated with Andrographis paniculata extract] inhibits the reaction [[Oxygen deficiency co-treated with Blood Glucose deficiency co-treated with Particulate Matter] results in decreased expression of PARPBP mRNA] and [Oxygen deficiency co-treated with Blood Glucose deficiency co-treated with Particulate Matter] results in decreased expression of PARPBP mRNA | CTD | PMID:33729688 | diquat | decreases expression | ISO | Parpbp (Mus musculus) | 6480464 | Diquat results in decreased expression of PARPBP mRNA | CTD | PMID:36851058 | Enterolactone | multiple interactions | ISO | PARPBP (Homo sapiens) | 6480464 | [Coumestrol co-treated with 2 and 3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of PARPBP mRNA | CTD | PMID:19167446 | fenvalerate | increases expression | EXP | | 6480464 | fenvalerate results in increased expression of PARPBP mRNA | CTD | PMID:30307764 | folic acid | multiple interactions | ISO | PARPBP (Homo sapiens) | 6480464 | [Folic Acid deficiency co-treated with Methotrexate] results in decreased expression of PARPBP mRNA | CTD | PMID:24657277 | formaldehyde | decreases expression | ISO | PARPBP (Homo sapiens) | 6480464 | Formaldehyde results in decreased expression of PARPBP mRNA | CTD | PMID:23649840 | furan | increases expression | EXP | | 6480464 | furan results in increased expression of PARPBP mRNA | CTD | PMID:25539665 | glyphosate | multiple interactions | EXP | | 6480464 | [azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased methylation of PARPBP gene | CTD | PMID:33854195 | hydrogen peroxide | affects expression | ISO | PARPBP (Homo sapiens) | 6480464 | Hydrogen Peroxide affects the expression of PARPBP mRNA | CTD | PMID:20044591 | imidacloprid | multiple interactions | EXP | | 6480464 | [azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased methylation of PARPBP gene | CTD | PMID:33854195 | indometacin | multiple interactions | ISO | PARPBP (Homo sapiens) | 6480464 | [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol S] results in decreased expression of PARPBP mRNA | CTD | PMID:28628672 | methotrexate | multiple interactions | ISO | PARPBP (Homo sapiens) | 6480464 | [Folic Acid deficiency co-treated with Methotrexate] results in decreased expression of PARPBP mRNA | CTD | PMID:24657277 | methyl methanesulfonate | increases expression | ISO | PARPBP (Homo sapiens) | 6480464 | Methyl Methanesulfonate results in increased expression of PARPBP mRNA | CTD | PMID:23649840 | N-Nitrosopyrrolidine | decreases expression | ISO | PARPBP (Homo sapiens) | 6480464 | N-Nitrosopyrrolidine results in decreased expression of PARPBP mRNA | CTD | PMID:32234424 | nickel atom | increases expression | ISO | PARPBP (Homo sapiens) | 6480464 | Nickel results in increased expression of PARPBP mRNA | CTD | PMID:25583101 | oxaliplatin | multiple interactions | EXP | | 6480464 | [oxaliplatin co-treated with Topotecan] results in decreased expression of PARPBP mRNA | CTD | PMID:25729387 | ozone | decreases expression | ISO | Parpbp (Mus musculus) | 6480464 | Ozone results in decreased expression of PARPBP mRNA | CTD | PMID:24336422 | ozone | multiple interactions | ISO | Parpbp (Mus musculus) | 6480464 | [Air Pollutants results in increased abundance of [Ozone co-treated with Soot]] which results in increased expression of PARPBP mRNA and [Air Pollutants results in increased abundance of Ozone] which results in increased expression of PARPBP mRNA | CTD | PMID:34911549 | paracetamol | increases expression | ISO | PARPBP (Homo sapiens) | 6480464 | Acetaminophen results in increased expression of PARPBP mRNA | CTD | PMID:22230336 | paracetamol | increases expression | EXP | | 6480464 | Acetaminophen results in increased expression of PARPBP mRNA | CTD | PMID:33387578 | PCB138 | multiple interactions | ISO | Parpbp (Mus musculus) | 6480464 | [2 more ... | CTD | PMID:25510870 | perfluorooctane-1-sulfonic acid | multiple interactions | ISO | Parpbp (Mus musculus) | 6480464 | [perfluorooctane sulfonic acid co-treated with Cellulose] results in increased expression of PARPBP mRNA | CTD | PMID:36331819 | quercetin | decreases expression | ISO | PARPBP (Homo sapiens) | 6480464 | Quercetin results in decreased expression of PARPBP mRNA | CTD | PMID:21632981 | resveratrol | multiple interactions | ISO | PARPBP (Homo sapiens) | 6480464 | [Coumestrol co-treated with resveratrol] results in increased expression of PARPBP mRNA | CTD | PMID:19167446 | silicon dioxide | increases expression | ISO | Parpbp (Mus musculus) | 6480464 | Silicon Dioxide results in increased expression of PARPBP mRNA | CTD | PMID:29341224 | sodium arsenite | decreases expression | ISO | PARPBP (Homo sapiens) | 6480464 | sodium arsenite results in decreased expression of PARPBP mRNA | CTD | PMID:29301061 | sunitinib | decreases expression | ISO | PARPBP (Homo sapiens) | 6480464 | Sunitinib results in decreased expression of PARPBP mRNA | CTD | PMID:31533062 | testosterone | multiple interactions | ISO | PARPBP (Homo sapiens) | 6480464 | [Testosterone co-treated with Calcitriol] results in decreased expression of PARPBP mRNA | CTD | PMID:21592394 | testosterone | multiple interactions | EXP | | 6480464 | [estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of PARPBP mRNA | CTD | PMID:32741896 | testosterone | decreases expression | ISO | PARPBP (Homo sapiens) | 6480464 | Testosterone results in decreased expression of PARPBP mRNA | CTD | PMID:21592394 | tetrachloromethane | increases expression | ISO | Parpbp (Mus musculus) | 6480464 | Carbon Tetrachloride results in increased expression of PARPBP mRNA | CTD | PMID:29987408 and PMID:31919559 | thiabendazole | multiple interactions | EXP | | 6480464 | [azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased methylation of PARPBP gene | CTD | PMID:33854195 | thimerosal | increases expression | ISO | PARPBP (Homo sapiens) | 6480464 | Thimerosal results in increased expression of PARPBP mRNA | CTD | PMID:27188386 | topotecan | decreases expression | EXP | | 6480464 | Topotecan results in decreased expression of PARPBP mRNA | CTD | PMID:25729387 | topotecan | multiple interactions | EXP | | 6480464 | [oxaliplatin co-treated with Topotecan] results in decreased expression of PARPBP mRNA | CTD | PMID:25729387 | trichloroethene | decreases expression | EXP | | 6480464 | Trichloroethylene results in decreased expression of PARPBP mRNA | CTD | PMID:33387578 | triptonide | increases expression | ISO | Parpbp (Mus musculus) | 6480464 | triptonide results in increased expression of PARPBP mRNA | CTD | PMID:33045310 | trovafloxacin | decreases expression | ISO | Parpbp (Mus musculus) | 6480464 | trovafloxacin results in decreased expression of PARPBP mRNA | CTD | PMID:35537566 | valproic acid | decreases expression | ISO | PARPBP (Homo sapiens) | 6480464 | Valproic Acid results in decreased expression of PARPBP mRNA | CTD | PMID:23179753 and PMID:27188386 | vorinostat | increases expression | ISO | PARPBP (Homo sapiens) | 6480464 | vorinostat results in increased expression of PARPBP mRNA | CTD | PMID:27188386 | |